# Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

> **NCT03611231** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 43 (estimated)

## Conditions studied

- Experimental Tumor

## Interventions

- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT03611231
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-01
- **Primary completion:** 2020-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2018-08-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03611231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03611231, "Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03611231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*